Safety Assessment of One-hour Infusions of SNS-032 for the Treatment of Select Advanced Solid Tumors

Exclusion Criteria

• •Prior exposure to SNS-032 (previously known as BMS-387032)
• •Pregnant or breastfeeding
• •Women or male partners of women who are able to have children but are unwilling to use an approved, effective means of birth control
• •Took part in another clinical trial during the last 21 days
• •Abnormal lab values for serum potassium, hemoglobin, neutrophils, platelets, creatinine, AST, ALT, or total bilirubin
• •Brain metastases, if patient is not neurologically stable or has needed corticosteroids or anticonvulsants at anytime within the 28 day period before enrollment.
• •Other active malignancies
• •Prior pelvic radiation therapy to ≥ 25% of bone marrow reserve
• •Any other condition that would keep the patient from safely taking part in the clinical trial